NL-OMON40143
Recruiting
Phase 2
Phase Ib/II study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer - OVMET
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- cancer of the ovaries
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 124
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with advanced stage (FIGO III\-IV), histologically confirmed and documented epithelial ovarian carcinoma
- •Patients eligible for neoadjuvant carboplatin/paclitaxel chemotherapy prior to surgical debulking (phase 1 or 2\) OR patients with relapsed or progressive ovarian cancer after initial treatment eligible for palliative carboplatin/paclitaxel chemotherapy (phase 1 only)
- •Measurable tumour according to RECISTv1\.1 or GCIG CA125 criteria (phase 2 only)
- •Eastern Cooperative Oncology Group\-performance status (ECOG\-PS) of 0\-2
- •Age \>\= 18 years
- •Adequate blood count, hepatic and renal function
- •Written informed consent
Exclusion Criteria
- •Prior chemotherapy, immunotherapy, targeted agents or radiotherapy to abdomen or pelvis (phase 2 only)
- •Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.
- •Metformin within 4 weeks prior to enrolment.
- •Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer (phase 2 only)
- •Symptomatic CNS metastasis
- •Pre\-existing peripheral neuropathy \>\= CTC grade 2\.
- •Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start.
- •Women of childbearing potential (defined as \<2 years after last menstruation and not surgically sterile) not using effective, non\-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the study and for 6 months after the last study medication.
- •Known hypersensitivity to any of the study drugs or excipients.
- •Serious active infection requiring i.v. antibiotics at enrolment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate the safety and effectivity of adding metformin to standard chemotherapy for advanced ovarian canceradvanced ovarian cancerMedDRA version: 16.1Level: PTClassification code 10070908Term: Ovarian cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10070907Term: Ovarian cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-005050-35-NLniversity Medical Center Groningen124
Suspended
Phase 1
A Randomised Double-Blind Controlled Trial of Metformin and Atorvastatin – with treatment commenced following prostatic biopsy and ceasing just before radical prostatectomy - to guide subsequent patient managementProstate cancerCancer - ProstateACTRN12615000571572niversity of Queensland Centre for Clinical Research80
Recruiting
Phase 3
empagliflozin effect in polycystic ovarian syndromPolycystic ovarian syndrome.Polycystic ovarian syndromeE28.2IRCT20220822055771N1Shahre-kord University of Medical Sciences50
Completed
Not Applicable
The effect of metformin and insulin in the prevention of preeclampsiaIRCT20220107053652N1Esfahan University of Medical Sciences150
Completed
Not Applicable
Comparison of therapeutic effects of metformin and simvastatin in PCOSPCOS.Polycystic ovarian syndromeIRCT201012285487N2Alzahra Hospital Research Center60